C-peptide immunoreactivity index is associated with improvement of HbA1c

2-Year follow-up of sitagliptin use in patients with type 2 diabetes

Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai, Hiroshi Itoh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]. ×. 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (. n=. 285) were: continuation of sitagliptin for ≥700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (δHbA1c ≤-0.4% [≤-4. mmol/mol]) and non-responder (δHbA1c >-0.4% [>-4. mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4. ±. 0.8% [57. ±. 9. mmol/mol], 7.3. ±. 0.9% [57. ±. 9. mmol/mol], 7.4. ±. 0.9% [58. ±. 10. mmol/mol], 7.1. ±. 0.8% [55. ±. 9. mmol/mol], and 7.3. ±. 0.9% [57. ±. 10. mmol/mol], respectively, all P<. 0.001 vs. baseline [8.0. ±. 1.0%, 64. ±. 11. mmol/mol] and CPR index: 1.69. ±. 0.96, 1.71. ±. 1.10, 1.62. ±. 0.96, 1.64. ±. 0.92, and 1.66. ±. 0.96, respectively, all P<. 0.05 vs. baseline [1.47. ±. 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response.

Original languageEnglish
Pages (from-to)441-447
Number of pages7
JournalDiabetes Research and Clinical Practice
Volume108
Issue number3
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

C-Peptide
Type 2 Diabetes Mellitus
Glucose
Sitagliptin Phosphate
Hypoglycemic Agents
Outpatients
Retrospective Studies
Logistic Models
Regression Analysis
Insulin
Serum

Keywords

  • C-peptide
  • Haemoglobin A1c protein
  • Human
  • Long-term effect
  • Sitagliptin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

@article{2354b99de45a49bd8321897aee6550c2,
title = "C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes",
abstract = "Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]. ×. 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (. n=. 285) were: continuation of sitagliptin for ≥700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (δHbA1c ≤-0.4{\%} [≤-4. mmol/mol]) and non-responder (δHbA1c >-0.4{\%} [>-4. mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4. ±. 0.8{\%} [57. ±. 9. mmol/mol], 7.3. ±. 0.9{\%} [57. ±. 9. mmol/mol], 7.4. ±. 0.9{\%} [58. ±. 10. mmol/mol], 7.1. ±. 0.8{\%} [55. ±. 9. mmol/mol], and 7.3. ±. 0.9{\%} [57. ±. 10. mmol/mol], respectively, all P<. 0.001 vs. baseline [8.0. ±. 1.0{\%}, 64. ±. 11. mmol/mol] and CPR index: 1.69. ±. 0.96, 1.71. ±. 1.10, 1.62. ±. 0.96, 1.64. ±. 0.92, and 1.66. ±. 0.96, respectively, all P<. 0.05 vs. baseline [1.47. ±. 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response.",
keywords = "C-peptide, Haemoglobin A1c protein, Human, Long-term effect, Sitagliptin",
author = "Takeshi Nishimura and Shu Meguro and Risa Sekioka and Karin Tanaka and Yoshifumi Saisho and Junichiro Irie and Masami Tanaka and Toshihide Kawai and Hiroshi Itoh",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.diabres.2015.02.031",
language = "English",
volume = "108",
pages = "441--447",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - C-peptide immunoreactivity index is associated with improvement of HbA1c

T2 - 2-Year follow-up of sitagliptin use in patients with type 2 diabetes

AU - Nishimura, Takeshi

AU - Meguro, Shu

AU - Sekioka, Risa

AU - Tanaka, Karin

AU - Saisho, Yoshifumi

AU - Irie, Junichiro

AU - Tanaka, Masami

AU - Kawai, Toshihide

AU - Itoh, Hiroshi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]. ×. 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (. n=. 285) were: continuation of sitagliptin for ≥700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (δHbA1c ≤-0.4% [≤-4. mmol/mol]) and non-responder (δHbA1c >-0.4% [>-4. mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4. ±. 0.8% [57. ±. 9. mmol/mol], 7.3. ±. 0.9% [57. ±. 9. mmol/mol], 7.4. ±. 0.9% [58. ±. 10. mmol/mol], 7.1. ±. 0.8% [55. ±. 9. mmol/mol], and 7.3. ±. 0.9% [57. ±. 10. mmol/mol], respectively, all P<. 0.001 vs. baseline [8.0. ±. 1.0%, 64. ±. 11. mmol/mol] and CPR index: 1.69. ±. 0.96, 1.71. ±. 1.10, 1.62. ±. 0.96, 1.64. ±. 0.92, and 1.66. ±. 0.96, respectively, all P<. 0.05 vs. baseline [1.47. ±. 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response.

AB - Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]. ×. 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (. n=. 285) were: continuation of sitagliptin for ≥700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (δHbA1c ≤-0.4% [≤-4. mmol/mol]) and non-responder (δHbA1c >-0.4% [>-4. mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4. ±. 0.8% [57. ±. 9. mmol/mol], 7.3. ±. 0.9% [57. ±. 9. mmol/mol], 7.4. ±. 0.9% [58. ±. 10. mmol/mol], 7.1. ±. 0.8% [55. ±. 9. mmol/mol], and 7.3. ±. 0.9% [57. ±. 10. mmol/mol], respectively, all P<. 0.001 vs. baseline [8.0. ±. 1.0%, 64. ±. 11. mmol/mol] and CPR index: 1.69. ±. 0.96, 1.71. ±. 1.10, 1.62. ±. 0.96, 1.64. ±. 0.92, and 1.66. ±. 0.96, respectively, all P<. 0.05 vs. baseline [1.47. ±. 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response.

KW - C-peptide

KW - Haemoglobin A1c protein

KW - Human

KW - Long-term effect

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84930180756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930180756&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2015.02.031

DO - 10.1016/j.diabres.2015.02.031

M3 - Article

VL - 108

SP - 441

EP - 447

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -